诺诚健华：佐来曲替尼在中国上市申请获批

Core Viewpoint - The company, Innovent Biologics, announced that its self-developed next-generation TRK inhibitor, Zolbetuximab (ICP-723), has received approval from the National Medical Products Administration of China, marking it as the first domestically developed next-generation TRK inhibitor approved for marketing in China [1] Group 1 - The new drug is intended for the treatment of adult and adolescent patients aged 12 and older with solid tumors carrying NTRK fusion genes [1]